30 Results for "

ADCP

" in MedChemExpress (MCE) Product Catalog:
Products (30)

30 Results for "ADCP" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-P99029
CAS No.: 2169232-81-7
Synonyms: Hu5F9-G4

Target:  

CD47

Research Areas:  

Cancer

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P72975
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99381
CAS No.: 1221901-33-2

Research Areas:  

Cancer

XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P82766
Synonyms: DPP4; ADCP2; CD26; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2; ADCP-2; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; CD26

Host:  

Rabbit

Application:  

WB

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-P9983
CAS No.: 166089-32-3
Synonyms: SGN-33; HuM-195; GLK-33 Antibody
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
loading...
    loading...
Cat. No.: HY-P99015
CAS No.: 880486-59-9

Target:  

TNF Receptor

Research Areas:  

Cancer

Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
loading...
    loading...
Cat. No.: HY-P990961
CAS No.: 2850355-87-0
Synonyms: IMM-2510; SYN-2510
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P991638

Target:  

TNF Receptor

Research Areas:  

Cancer

XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
loading...
    loading...
Cat. No.: HY-P991555

Target:  

TNF Receptor Apoptosis

Research Areas:  

Cancer

XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
loading...
    loading...
Cat. No.: HY-P991942
Synonyms: BAY3375968; TPP-23411

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P81529
Synonyms: ADCP2, CD26; DPP4; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2 (ADCP-2); Dipeptidyl peptidase IV (DPP IV); T-cell activation antigen CD26; TP103

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P81529A
Synonyms: ADCP2, CD26; DPP4; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2 (ADCP-2); Dipeptidyl peptidase IV (DPP IV); T-cell activation antigen CD26; TP103

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P84979
Synonyms: DPP4; ADCP2; CD26; Dipeptidyl peptidase 4; ADABP; Adenosine deaminase complexing protein 2; ADCP-2; Dipeptidyl peptidase IV; DPP IV; T-cell activation antigen CD26; TP103; CD26; CD26 nanobody;

Host:  

Mouse

Application:  

ELISA, FC

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P991942A
Synonyms: BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)

Target:  

CCR

Research Areas:  

Cancer

Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P991898
Synonyms: RD126

Target:  

CD19

Research Areas:  

Inflammation/Immunology

IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
loading...
    loading...
Cat. No.: HY-P991954

Target:  

Complement System Syk

Research Areas:  

Inflammation/Immunology Cancer

GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P72976
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P75429
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Dipeptidyl peptidase 4; ADABP; ADCP-2; DPP IV; TP103; CD26; DPP4
Species:  
Source:  
loading...
    loading...